单剂布地奈德/福莫特罗与沙丁胺醇对哮喘支气管扩张起效速度比较:随机交叉试验
该双盲、交叉、单中心、安慰剂对照非劣效性试验纳入49例稳定期哮喘成人,比较布地奈德/福莫特罗200/6 µg(Turbuhaler)与沙丁胺醇200 µg(pMDI)后2分钟FEV1变化。结果显示布地奈德/福莫特罗2分钟FEV1改善低于沙丁胺醇,配对差值-0.097 L(95%CI -0.147至-0.047),未达到-0.06 L非劣效界值;30分钟内FEV1也较低。
要点
- 布地奈德/福莫特罗2分钟FEV1改善未达非劣效界值,结果不支持其与沙丁胺醇起效非劣效。
- 30分钟内FEV1沙丁胺醇组更高,差值-0.10 L(95%CI -0.12至-0.08),p<0.001。
- 两种治疗在呼吸困难视觉模拟评分和mBorg评分上无差异。
核心结论
- 结果不支持布地奈德/福莫特罗200/6 µg与沙丁胺醇200 µg在2分钟FEV1差值-0.06 L界值上的非劣效性,p=0.07可能与劣效性一致。
- 次要分析显示30分钟内FEV1沙丁胺醇组更高。
研究设计与样本
- 双盲、交叉、单中心、安慰剂对照、非劣效性试验。
- 纳入稳定期哮喘成人,随机分配至两种治疗顺序:安慰剂MDI两揿+布地奈德/福莫特罗200/6 µg Turbuhaler一吸;安慰剂Turbuhaler一吸+沙丁胺醇100 µg MDI两揿。
- 50例潜在参与者中49例被随机,1例在首次干预访视后退出,另1例因COVID-19限制未能随机。
- 主要结局为2分钟时FEV1,次要结局包括30分钟内FEV1、mBorg呼吸困难量表评分和呼吸困难视觉模拟评分。
主要发现
- 布地奈德/福莫特罗组2分钟FEV1较基线平均变化0.08 L(SD 0.14),n=49;沙丁胺醇组0.17 L(SD 0.18),n=48。
- 配对差值均值-0.097 L(95%CI -0.147至-0.047),p=0.07,非劣效界值为-0.06 L。
- 30分钟内FEV1布地奈德/福莫特罗低于沙丁胺醇,差值-0.10 L(95%CI -0.12至-0.08),p<0.001。
- 两种治疗间呼吸困难视觉模拟评分和mBorg呼吸困难量表评分无差异。
关键数值与推荐
- 非劣效界值:2分钟FEV1配对差值-0.06 L。
- 主要结局配对差值均值-0.097 L(95%CI -0.147至-0.047),p=0.07。
- 30分钟FEV1差值-0.10 L(95%CI -0.12至-0.08),p<0.001。
临床怎么用
- 对于稳定期哮喘成人,若需快速支气管扩张,本试验结果不支持布地奈德/福莫特罗200/6 µg替代沙丁胺醇200 µg用于2分钟内的快速缓解。
- 临床选择缓解药物时应考虑起效速度差异,沙丁胺醇在30分钟内FEV1改善更优。
局限性
- 单中心研究,样本量有限(随机49例,主要分析n=49/48)。
- 部分参与者因COVID-19限制未能随机。
- 结果为2分钟和30分钟内短期指标,未报告长期临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare bronchodilator response after to salbutamol and budesonide/formoterol in adults with stable asthma. METHODS: A double-blind, cross-over, single-centre, placebo-controlled, non-inferiority trial. Adults with stable asthma were randomised to different orders of two treatment regimens: two actuations of placebo via MDI and one actuation of budesonide/formoterol 200/6 µg via turbuhaler; and one actuation of placebo turbuhaler and two actuations of salbutamol 100 µg via MDI. The primary outcome measure was FEV1 after 2 min. Secondary outcome measures included FEV1, mBorg Dyspnoea Scale score and visual analogue score for breathlessness over 30 min. RESULTS: Forty-nine of 50 potential participants were randomised. One participant withdrew following the first intervention visit and another could not be randomised due to COVID-19 restrictions. The mean (SD) change from baseline FEV1 2 min after treatment administration for budesonide/formoterol and salbutamol was 0.08 (0.14) L, n=49, and 0.17 (0.18) L, n=48, respectively, mean (95% CI) paired difference of -0.097 L (-0.147 to -0.047), p=0.07, against a non-inferiority bound of -0.06 L. In the secondary analysis, FEV1 over 30 min was lower for budesonide/formoterol compared with salbutamol, difference (95% CI): -0.10 (-0.12 to -0.08) L, p<0.001. There were no differences in Visual Analogue Scale score or mBorg Dyspnoea Scale score between treatments. CONCLUSION: The results do not support the primary hypothesis of non-inferiority at the boundary of -0.06 L for the difference between budesonide/formoterol 200/6 µg compared with salbutamol 200 µg for FEV1 at 2 min, and could be consistent with inferiority with a p value of 0.07. For the secondary analysis of FEV1 measurements over time, the FEV1 was higher with salbutamol. TRIAL REGISTRATION NUMBER: Australian and New Zealand Clinical Trials Registry (ACTRN 12619001387112).
引用
- Kearns N, Williams M, Bruce P, et al. Single dose of budesonide/formoterol turbuhaler compared to salbutamol pMDI for speed of bronchodilator onset in asthma: a randomised cross-over trial. Thorax. 2022. PMID: 35851045. doi:10.1136/thorax-2022-219052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。